Monarch Medical Technologies Announces New Chief Executive Officer

Business Wire

CHARLOTTE, N.C.--(BUSINESS WIRE)-- Monarch Medical Technologies, the market-leading clinical decision support software committed to the safest insulin dosing, today announced that Linda Beneze has joined the company as its new chief executive officer. Formerly the Chief Executive Officer at Medical Technology Products, Beneze has extensive experience building and leading global high-performance teams with expertise in medical device, clinical trial software, bioinformatics, and data management.

“After an extensive selection process, we are delighted to have Linda Beneze lead the company in an evolving and expanding market of inpatient glycemic control. Linda brings a wealth of experience in improving outcomes and enhancing patient and provider safety, alongside her unique blend of leadership experience,” said Christophe Mallard, managing member of private investment firm Eigen Capital Holdings LLC which controls Monarch Medical Technologies. “Linda shares our commitment to patient safety, passion for improving hospital outcomes, and excitement for our future. We look forward to strong continued growth under her leadership.”

With more than 35 years of experience in healthcare, Beneze is well-versed in strategic planning and execution, product innovation, market leadership, and business development. Prior to her tenure at Medical Technology Products, she was the President & General Manager of the Specialty Division at Teleflex, Inc. and has also held executive positions at healthcare companies including KIKA Clinical Solutions, PHT, Inc., Phase Forward, Inc., and C.R. Bard.

“I am very excited to join such an innovative and passionate company. I have seen the impact EndoTool has made on improving outcomes relative to glycemic control and I am honored to accept this opportunity to lead Monarch’s team of experts to thrive in the years to come,” Beneze said.

About Monarch Medical Technologies

Monarch Medical Technologies is the leading provider of clinical decision support for inpatient glycemic management and the emerging leader as the world’s safest prescriptive drug dosing platform. With over 60 combined algorithms developed by a team of practicing doctors and mathematicians, Monarch’s EndoTool® Glucose Management System ensures that dosing is individualized and responsive to ongoing changes in each patient’s unique physiological response. As a Class II FDA-approved, patent pending software suite, EndoTool allows hospitals and care providers to provide unsurpassed patient-specific glycemic control across a broad population of patients. This technology is doing more than changing the conversation in over 170 hospitals— it’s helping providers achieve the coveted Triple Aim of better health, better care, at a lower cost.